Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company
Memorial Sloan Kettering Cancer Center
Wake Forest University Health Sciences
University of Alabama at Birmingham
Washington University School of Medicine
National Institutes of Health Clinical Center (CC)
Roswell Park Cancer Institute
Novita Pharmaceuticals, Inc.
M.D. Anderson Cancer Center
Bayer
Mayo Clinic
Novartis
Anaveon AG
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Imunon
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Northwestern University
Genmab
Janssen Pharmaceutical K.K.
Massachusetts General Hospital
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Janssen Research & Development, LLC
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Case Comprehensive Cancer Center
Georgetown University
Weill Medical College of Cornell University
Genmab
Genmab
Merck Sharp & Dohme LLC
Autolus Limited
Genmab
Genmab
Astellas Pharma Inc